<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="238969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002342</url>
  </required_header>
  <id_info>
    <org_study_id>088C</org_study_id>
    <secondary_id>4152A-PRT004</secondary_id>
    <nct_id>NCT00002342</nct_id>
  </id_info>
  <brief_title>A Study of Tecogalan Sodium</brief_title>
  <official_title>A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152)
      and to establish the MTD at each of the different dosing schedules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2
      weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be
      obtained from patients with Kaposi's sarcoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecogalan sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.

          -  Life expectancy of at least 12 weeks.

          -  NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.

          -  Recovered from toxicity of any prior anticancer therapy.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Leukemia or lymphoma.

          -  Current gastrointestinal bleeding by stool guaiac.

          -  Extensive bone metastases or significant radiographic osteoporosis in patients with
             solid tumors.

          -  Active heart disease such as uncontrolled angina, uncompensated congestive heart
             failure, or dysrhythmias requiring antiarrhythmics.

          -  Acute intercurrent infection other than genital herpes.

          -  Symptomatic or known central nervous system involvement (including brain metastases)
             unless stable and off therapy.

        Concurrent Medication:

        Excluded:

          -  Other anticancer therapy.

          -  Other investigational agents.

        Patients with the following prior conditions are excluded:

          -  History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease.

          -  History of myocardial infarction within past 6 months.

        Prior Medication:

        Excluded:

          -  Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).

          -  Investigational agents within the past 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1996</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <keyword>Neoplasms</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>tecogalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
